Since our present study showed the involvement of the CXCR3 pathway in increased susceptibility to inflammation, antagonists of CXCR3 or monoclonal antibodies against CXCL10 might be effective for treating patients with PRAAS. Here, CXCR3 is linked to proteosome-associated autoinflammatory syndrome.